The Platform Technology Designation Program for Drug Development Guidance for Industry of the United States and its implications for the regulation of cell and gene therapy in ChinaMA Qiao-ning, SUN Tan-lin, WANG Wen-ya337-340
Construction and considerations on efficacy evaluation indicator system of Chinese medicine syndromeWANG Jian-xin, DAI Xin-yue, SUN Ming-yue, LV Xing, GUO Man-ping, ZI Ming-jie, YANG Qiao-ning, GAO Rui341-345
Analysis of the drug patent term extension provisions in the context of the new Detailed Rules for the Implementation of the Patent Law of the People's Republic of China and Patent Examination GuidelinesSUN Ming-ming346-351
Problems and thoughts on clinical data in the filing of traditional Chinese medicine preparations using traditional techniques in medical institutionsLI Si-qi, ZHOU Meng-yue, YANG Fang-fang, ZHANG Zhi-yu, PAN Ding-ju352-357
Research on defense of uncertainty to patent infringement of generic drug commissioned developmentJIN Chun-yang, HE An-qi358-363
A selective inhibitor of cyclin-dependent kinases 4/6,ribociclib,for the treatment of breast cancerLI Yan, CUI Ying-jie, LIU Juan-juan, ZHAO Hui, WANG Zhen-zhen, ZHOU Yi, ZHANG Jing364-369
Exploration of the full life cycle management of drug guidance by the U.S.FDA and its inspiration to ChinaSUN Tan-lin, MA Qiao-ning, XU Zhen-yu370-376
Evaluation and optimization of anti-breast cancer effect of dendritic cell vaccine derived from cord blood CD34+hematopoietic stem cells in vitroWANG Miao, XIE Hui-ping, YAN Ke-qing, CUI Hong-fei, LI Wei, ZHANG Zhi-fei, JIN Yuan-yuan377-385
Research progress in organ-on-a-chip and its application in the development of new drugsZHANG Shi-long, LE Le, LIANG Xu-rui, ZHANG Xiao-wei, ZUO Zhi-qiang, ZHANG Tao386-393
The application of error-corrected duplex sequencing in genetic toxicity and carcinogenicityCUI Wen-teng, ZHENG Ming-lan, ZHOU Chang-hui, HE Wei-wei, FANG Ya-li, FENG Tian-yi, DU Hong-li, CHANG Yan394-400